Noxopharm Limited (NOXOF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -7.53 Million AUD | 54.59% |
| 2023 | -16.59 Million AUD | -9.12% |
| 2022 | -15.2 Million AUD | -4.09% |
| 2021 | -14.6 Million AUD | 10.73% |
| 2020 | -16.36 Million AUD | -4.47% |
| 2019 | -15.66 Million AUD | -49.19% |
| 2018 | -10.5 Million AUD | -225.27% |
| 2017 | -3.22 Million AUD | -359.17% |
| 2016 | -703.07 Thousand AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -1.91 Million AUD | 44.88% |
| 2024 FY | -7 Million AUD | 57.81% |
| 2024 Q1 | -1.12 Million AUD | 85.19% |
| 2024 Q2 | -3.47 Million AUD | -207.31% |
| 2024 Q4 | -1.91 Million AUD | 0.0% |
| 2023 FY | -16.59 Million AUD | -9.12% |
| 2023 Q3 | -2.51 Million AUD | 71.97% |
| 2023 Q4 | -7.62 Million AUD | -203.54% |
| 2023 Q2 | -8.96 Million AUD | -219.07% |
| 2023 Q1 | -2.8 Million AUD | 67.61% |
| 2022 Q2 | -6.53 Million AUD | -175.4% |
| 2022 Q4 | -8.67 Million AUD | -244.61% |
| 2022 FY | -15.2 Million AUD | -4.09% |
| 2022 Q1 | -2.37 Million AUD | 71.93% |
| 2022 Q3 | -2.51 Million AUD | 61.48% |
| 2021 Q2 | -7.45 Million AUD | -144.4% |
| 2021 FY | -14.6 Million AUD | 10.73% |
| 2021 Q3 | -4.24 Million AUD | 43.09% |
| 2021 Q4 | -8.45 Million AUD | -99.08% |
| 2021 Q1 | -3.05 Million AUD | 53.91% |
| 2020 Q4 | -6.62 Million AUD | -530.14% |
| 2020 FY | -16.36 Million AUD | -4.47% |
| 2020 Q2 | -9.74 Million AUD | -225.78% |
| 2020 Q1 | -2.99 Million AUD | 63.41% |
| 2020 Q3 | -1.05 Million AUD | 89.22% |
| 2019 Q1 | -2.11 Million AUD | 23.94% |
| 2019 Q4 | -8.17 Million AUD | -112.68% |
| 2019 Q3 | -3.84 Million AUD | -81.8% |
| 2019 Q2 | -2.11 Million AUD | 0.0% |
| 2019 FY | -15.66 Million AUD | -49.19% |
| 2018 Q4 | -2.77 Million AUD | 0.0% |
| 2018 FY | -10.5 Million AUD | -225.27% |
| 2018 Q1 | -2.01 Million AUD | -107.12% |
| 2018 Q2 | -2.01 Million AUD | 0.0% |
| 2018 Q3 | -2.77 Million AUD | -38.14% |
| 2017 FY | -3.22 Million AUD | -359.17% |
| 2017 Q1 | -579.47 Thousand AUD | 3.44% |
| 2017 Q4 | -971.52 Thousand AUD | 0.0% |
| 2017 Q2 | -579.47 Thousand AUD | 0.0% |
| 2017 Q3 | -971.52 Thousand AUD | -67.66% |
| 2016 FY | -703.07 Thousand AUD | 0.0% |
| 2016 Q2 | -96.25 Thousand AUD | 0.0% |
| 2016 Q4 | -600.12 Thousand AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bioxytran, Inc. | -3.82 Million USD | -97.244% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 89.504% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -2778.966% |
| SQZ Biotechnologies Company | -75.82 Million USD | 90.063% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -164.339% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 57.78% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 109.206% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -390.544% |
| Marizyme, Inc. | -34.08 Million USD | 77.894% |
| Genus plc | 6.4 Million USD | 217.734% |
| Pharming Group N.V. | -4.87 Million USD | -54.42% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -279.314% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -709.015% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 9.76% |
| ContraFect Corporation | -56.88 Million USD | 86.755% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -437.45% |
| IMV Inc. | -38.67 Million USD | 80.515% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -173.917% |
| ONE Bio Corp. | 13.68 Million USD | 155.074% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 87.227% |
| Mesoblast Limited | -84.14 Million USD | 91.045% |
| MultiCell Technologies, Inc. | -722.81 USD | -1042359.568% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 312.853% |
| Genscript Biotech Corporation | -415.79 Million USD | 98.188% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -1834.184% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -186.772% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 253.312% |
| Biomind Labs Inc. | -1 Million USD | -646.333% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -159.716% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -13.342% |
| Skye Bioscience, Inc. | -13.67 Million USD | 44.887% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -304.158% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 177.342% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -25056.924% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -65.433% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -49.371% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 52.52% |
| Accustem Sciences Inc. | -3.74 Million USD | -101.125% |
| EV Biologics, Inc. | -483.06 Thousand USD | -1459.842% |
| Q BioMed Inc. | -3.44 Million USD | -118.684% |
| GB Sciences, Inc. | -1.42 Million USD | -430.444% |
| Alpha Cognition Inc. | -9.7 Million USD | 22.364% |
| CSL Limited | 3.7 Billion USD | 100.204% |
| Agentix Corp. | -1.37 Million USD | -449.296% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 86.293% |
| Enzolytics Inc. | -2.14 Million USD | -250.661% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | -12.74 Million USD | 40.897% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -137.827% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -289.887% |
| argenx SE | -425.04 Million USD | 98.227% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 86.425% |
| HST Global, Inc. | -140.9 Thousand USD | -5247.5% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -621.743% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -569.834% |
| Halberd Corporation | -75.05 Thousand USD | -9939.976% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -158.097% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -121.294% |
| Zenith Capital Corp. | -8.94 Million USD | 15.744% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -377.094% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -206.885% |
| AVAX Technologies, Inc. | 6.69 Million USD | 212.582% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -4293.343% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -275.856% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -43152.408% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -2.46 Million USD | -205.461% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -665.711% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -499.921% |
| Kadimastem Ltd | -3.04 Million USD | -147.842% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | 3.136% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -4051.859% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -464.237% |
| LadRx Corporation | -3.82 Million USD | -97.064% |
| Cell Source, Inc. | -4.32 Million USD | -74.206% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1713.57% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -996.878% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -996.878% |
| Affymax, Inc. | -15.04 Million USD | 49.92% |
| Mobile Lads Corp. | -554.55 Thousand USD | -1258.76% |
| Itoco Inc. | -919.14 Thousand USD | -719.788% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -77.779% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -573.369% |
| International Stem Cell Corporation | -663 Thousand USD | -1036.501% |
| CytoDyn Inc. | -18.05 Million USD | 58.273% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -29836.44% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -3323.787% |
| Qrons Inc. | -643.67 Thousand USD | -1070.618% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -1234.283% |
| SYBLEU INC | -149.18 Thousand USD | -4950.947% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -237.911% |
| Rebus Holdings, Inc. | -664 Thousand USD | -1034.789% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -314.85% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -14214.214% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -36945.241% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 79.223% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -365.699% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -924.007% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -142.205% |
| Neutra Corp. | -229.48 Thousand USD | -3183.426% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 57.039% |
| PureTech Health plc | -146.19 Million USD | 94.846% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 64.939% |
| IXICO plc | -1.43 Million USD | -424.356% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 20.609% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 93.814% |
| CSL Limited | 3.81 Billion USD | 100.198% |
| Cellectis S.A. | -108.85 Million USD | 93.078% |